Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1315.25
12.25 (0.94%) Dr. Reddy’s Laboratories informs about press release
Date: 21-10-2026Dr. Reddy’s Laboratories has informed that it enclosed a Press Release ‘Dr. Reddy’s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India’.
The above information is a part of company’s filings submitted to BSE.